Annual FCF
-$97.31 M
+$65.89 M+40.37%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual free cash flow is currently -$97.31 million, with the most recent change of +$65.89 million (+40.37%) on 31 December 2023. During the last 3 years, it has risen by +$47.23 million (+32.68%). BCRX annual FCF is now -2015.41% below its all-time high of -$4.60 million, reached on 31 December 1998.BCRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$8.19 M
+$9.71 M+637.49%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly free cash flow is currently $8.19 million, with the most recent change of +$9.71 million (+637.49%) on 30 September 2024. Over the past year, it has increased by +$17.66 million (+186.42%). BCRX quarterly FCF is now -68.22% below its all-time high of $25.75 million, reached on 31 March 2006.BCRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$56.73 M
+$29.07 M+33.88%
30 September 2024
Summary:
BioCryst Pharmaceuticals TTM free cash flow is currently -$56.73 million, with the most recent change of +$29.07 million (+33.88%) on 30 September 2024. Over the past year, it has increased by +$40.58 million (+41.70%). BCRX TTM FCF is now -814.81% below its all-time high of $7.94 million, reached on 31 March 2006.BCRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +186.4% | +41.7% |
| 3 y3 years | +32.7% | +124.4% | +60.8% |
| 5 y5 years | -8.2% | +177.8% | +36.9% |
BCRX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +40.4% | at high | +110.5% | at high | +67.1% |
| 5 y | 5 years | -8.2% | +40.4% | at high | +110.5% | at high | +67.3% |
| alltime | all time | -2015.4% | +40.4% | -68.2% | +110.5% | -814.8% | +67.3% |
BioCryst Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.19 M(-637.5%) | -$56.73 M(-33.9%) |
| June 2024 | - | -$1.52 M(-97.2%) | -$85.80 M(-17.1%) |
| Mar 2024 | - | -$53.92 M(+469.2%) | -$103.56 M(+6.4%) |
| Dec 2023 | -$97.31 M(-40.4%) | -$9.47 M(-54.6%) | -$97.31 M(-13.3%) |
| Sept 2023 | - | -$20.88 M(+8.3%) | -$112.21 M(-9.5%) |
| June 2023 | - | -$19.28 M(-59.6%) | -$123.95 M(-6.6%) |
| Mar 2023 | - | -$47.67 M(+95.6%) | -$132.67 M(-18.7%) |
| Dec 2022 | -$163.20 M(+12.9%) | -$24.38 M(-25.3%) | -$163.20 M(-5.3%) |
| Sept 2022 | - | -$32.62 M(+16.5%) | -$172.39 M(+5.5%) |
| June 2022 | - | -$28.00 M(-64.2%) | -$163.41 M(+1.1%) |
| Mar 2022 | - | -$78.21 M(+133.0%) | -$161.64 M(+11.8%) |
| Dec 2021 | -$144.54 M(+6.6%) | -$33.57 M(+42.0%) | -$144.54 M(-5.9%) |
| Sept 2021 | - | -$23.64 M(-9.8%) | -$153.66 M(-8.8%) |
| June 2021 | - | -$26.22 M(-57.1%) | -$168.45 M(-2.8%) |
| Mar 2021 | - | -$61.11 M(+43.2%) | -$173.34 M(+27.8%) |
| Dec 2020 | -$135.62 M(+50.8%) | -$42.69 M(+11.1%) | -$135.62 M(+31.1%) |
| Sept 2020 | - | -$38.43 M(+23.5%) | -$103.46 M(+11.5%) |
| June 2020 | - | -$31.11 M(+33.0%) | -$92.76 M(+7.6%) |
| Mar 2020 | - | -$23.40 M(+122.2%) | -$86.23 M(-4.1%) |
| Dec 2019 | -$89.93 M(-3.2%) | -$10.53 M(-62.0%) | -$89.93 M(-13.1%) |
| Sept 2019 | - | -$27.72 M(+12.7%) | -$103.49 M(-6.6%) |
| June 2019 | - | -$24.59 M(-9.2%) | -$110.84 M(+10.5%) |
| Mar 2019 | - | -$27.09 M(+12.5%) | -$100.33 M(+8.0%) |
| Dec 2018 | -$92.93 M(+124.1%) | -$24.09 M(-31.3%) | -$92.93 M(+16.9%) |
| Sept 2018 | - | -$35.07 M(+149.1%) | -$79.48 M(+39.4%) |
| June 2018 | - | -$14.08 M(-28.5%) | -$57.02 M(+8.3%) |
| Mar 2018 | - | -$19.69 M(+85.1%) | -$52.63 M(+26.9%) |
| Dec 2017 | -$41.47 M(-29.4%) | -$10.63 M(-15.7%) | -$41.47 M(+13.0%) |
| Sept 2017 | - | -$12.62 M(+30.3%) | -$36.69 M(-12.2%) |
| June 2017 | - | -$9.69 M(+13.6%) | -$41.81 M(-7.4%) |
| Mar 2017 | - | -$8.53 M(+45.7%) | -$45.14 M(-23.1%) |
| Dec 2016 | -$58.72 M(+221.9%) | -$5.85 M(-67.0%) | -$58.72 M(-18.2%) |
| Sept 2016 | - | -$17.74 M(+36.2%) | -$71.74 M(+7.4%) |
| June 2016 | - | -$13.02 M(-41.1%) | -$66.80 M(+85.3%) |
| Mar 2016 | - | -$22.10 M(+17.1%) | -$36.05 M(+97.7%) |
| Dec 2015 | -$18.24 M(-52.8%) | -$18.87 M(+47.4%) | -$18.24 M(+36.9%) |
| Sept 2015 | - | -$12.80 M(-172.2%) | -$13.32 M(+45.5%) |
| June 2015 | - | $17.73 M(-513.2%) | -$9.15 M(-73.1%) |
| Mar 2015 | - | -$4.29 M(-69.3%) | -$33.98 M(-12.1%) |
| Dec 2014 | -$38.66 M(+45.5%) | -$13.96 M(+61.6%) | -$38.66 M(+32.3%) |
| Sept 2014 | - | -$8.63 M(+21.6%) | -$29.22 M(+2.5%) |
| June 2014 | - | -$7.10 M(-20.8%) | -$28.51 M(+17.2%) |
| Mar 2014 | - | -$8.97 M(+98.4%) | -$24.33 M(-8.4%) |
| Dec 2013 | -$26.56 M(-29.2%) | -$4.52 M(-43.0%) | -$26.56 M(-8.6%) |
| Sept 2013 | - | -$7.92 M(+171.2%) | -$29.07 M(-11.7%) |
| June 2013 | - | -$2.92 M(-73.9%) | -$32.93 M(-9.5%) |
| Mar 2013 | - | -$11.20 M(+59.3%) | -$36.39 M(-3.0%) |
| Dec 2012 | -$37.51 M(+16.1%) | -$7.03 M(-40.4%) | -$37.51 M(+8.8%) |
| Sept 2012 | - | -$11.78 M(+84.6%) | -$34.47 M(+4.0%) |
| June 2012 | - | -$6.38 M(-48.2%) | -$33.15 M(+9.5%) |
| Mar 2012 | - | -$12.32 M(+209.1%) | -$30.27 M(-6.3%) |
| Dec 2011 | -$32.31 M(+11.9%) | -$3.98 M(-61.9%) | -$32.31 M(-5.4%) |
| Sept 2011 | - | -$10.47 M(+199.7%) | -$34.15 M(+3.6%) |
| June 2011 | - | -$3.49 M(-75.7%) | -$32.98 M(-13.1%) |
| Mar 2011 | - | -$14.36 M(+146.1%) | -$37.97 M(+31.5%) |
| Dec 2010 | -$28.88 M(+71.7%) | -$5.83 M(-37.2%) | -$28.88 M(+113.9%) |
| Sept 2010 | - | -$9.29 M(+9.5%) | -$13.50 M(+42.5%) |
| June 2010 | - | -$8.48 M(+60.9%) | -$9.48 M(-26.8%) |
| Mar 2010 | - | -$5.27 M(-155.2%) | -$12.94 M(-23.1%) |
| Dec 2009 | -$16.82 M | $9.54 M(-281.2%) | -$16.82 M(-45.7%) |
| Sept 2009 | - | -$5.27 M(-55.9%) | -$30.98 M(-3.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$11.94 M(+30.5%) | -$32.08 M(+20.7%) |
| Mar 2009 | - | -$9.15 M(+98.6%) | -$26.58 M(+20.3%) |
| Dec 2008 | -$22.09 M(-22.1%) | -$4.61 M(-27.6%) | -$22.09 M(-36.9%) |
| Sept 2008 | - | -$6.37 M(-1.2%) | -$34.97 M(+1.2%) |
| June 2008 | - | -$6.45 M(+38.2%) | -$34.56 M(+17.8%) |
| Mar 2008 | - | -$4.67 M(-73.3%) | -$29.33 M(+3.5%) |
| Dec 2007 | -$28.34 M(+69.2%) | -$17.50 M(+194.0%) | -$28.34 M(+7.7%) |
| Sept 2007 | - | -$5.95 M(+389.1%) | -$26.32 M(-21.6%) |
| June 2007 | - | -$1.22 M(-66.9%) | -$33.56 M(-27.3%) |
| Mar 2007 | - | -$3.67 M(-76.3%) | -$46.17 M(+175.7%) |
| Dec 2006 | -$16.75 M(-28.4%) | -$15.47 M(+17.2%) | -$16.75 M(+142.8%) |
| Sept 2006 | - | -$13.20 M(-4.5%) | -$6.90 M(<-9900.0%) |
| June 2006 | - | -$13.83 M(-153.7%) | $61.10 K(-99.2%) |
| Mar 2006 | - | $25.75 M(-557.9%) | $7.94 M(-133.9%) |
| Dec 2005 | -$23.40 M(+27.0%) | -$5.62 M(-9.9%) | -$23.40 M(+0.4%) |
| Sept 2005 | - | -$6.24 M(+4.9%) | -$23.30 M(+11.2%) |
| June 2005 | - | -$5.95 M(+6.7%) | -$20.94 M(+6.5%) |
| Mar 2005 | - | -$5.58 M(+0.9%) | -$19.66 M(+6.7%) |
| Dec 2004 | -$18.43 M(+63.8%) | -$5.53 M(+42.1%) | -$18.43 M(+17.9%) |
| Sept 2004 | - | -$3.89 M(-16.8%) | -$15.63 M(+5.8%) |
| June 2004 | - | -$4.67 M(+7.6%) | -$14.77 M(+14.4%) |
| Mar 2004 | - | -$4.34 M(+59.3%) | -$12.91 M(+14.8%) |
| Dec 2003 | -$11.25 M(-32.9%) | -$2.73 M(-10.2%) | -$11.25 M(+4.4%) |
| Sept 2003 | - | -$3.03 M(+8.0%) | -$10.77 M(-3.0%) |
| June 2003 | - | -$2.81 M(+4.8%) | -$11.10 M(-15.7%) |
| Mar 2003 | - | -$2.68 M(+19.1%) | -$13.17 M(-21.5%) |
| Dec 2002 | -$16.77 M(+31.4%) | -$2.25 M(-33.1%) | -$16.77 M(-9.7%) |
| Sept 2002 | - | -$3.36 M(-31.1%) | -$18.58 M(+0.5%) |
| June 2002 | - | -$4.88 M(-22.3%) | -$18.49 M(+14.1%) |
| Mar 2002 | - | -$6.28 M(+54.9%) | -$16.20 M(+26.9%) |
| Dec 2001 | -$12.76 M(+116.3%) | -$4.06 M(+23.9%) | -$12.76 M(+10.0%) |
| Sept 2001 | - | -$3.27 M(+26.4%) | -$11.60 M(+2.2%) |
| June 2001 | - | -$2.59 M(-8.8%) | -$11.34 M(+4.8%) |
| Mar 2001 | - | -$2.84 M(-1.7%) | -$10.82 M(+83.4%) |
| Dec 2000 | -$5.90 M(+0.0%) | -$2.89 M(-4.3%) | -$5.90 M(+54.9%) |
| Sept 2000 | - | -$3.02 M(+46.2%) | -$3.81 M(+27.5%) |
| June 2000 | - | -$2.07 M(-199.5%) | -$2.99 M(+192.5%) |
| Mar 2000 | - | $2.08 M(-359.8%) | -$1.02 M(-82.7%) |
| Dec 1999 | -$5.90 M(+28.3%) | -$800.00 K(-63.6%) | -$5.90 M(+490.0%) |
| Sept 1999 | - | -$2.20 M(+2100.0%) | -$1.00 M(-41.2%) |
| June 1999 | - | -$100.00 K(-96.4%) | -$1.70 M(-63.0%) |
| Mar 1999 | - | -$2.80 M(-168.3%) | -$4.60 M(0.0%) |
| Dec 1998 | -$4.60 M(-59.6%) | $4.10 M(-241.4%) | -$4.60 M(-61.0%) |
| Sept 1998 | - | -$2.90 M(-3.3%) | -$11.80 M(+2.6%) |
| June 1998 | - | -$3.00 M(+7.1%) | -$11.50 M(+7.5%) |
| Mar 1998 | - | -$2.80 M(-9.7%) | -$10.70 M(-6.1%) |
| Dec 1997 | -$11.40 M(+60.6%) | -$3.10 M(+19.2%) | -$11.40 M(+14.0%) |
| Sept 1997 | - | -$2.60 M(+18.2%) | -$10.00 M(+2.0%) |
| June 1997 | - | -$2.20 M(-37.1%) | -$9.80 M(+14.0%) |
| Mar 1997 | - | -$3.50 M(+105.9%) | -$8.60 M(+21.1%) |
| Dec 1996 | -$7.10 M(-10.1%) | -$1.70 M(-29.2%) | -$7.10 M(+1.4%) |
| Sept 1996 | - | -$2.40 M(+140.0%) | -$7.00 M(+7.7%) |
| June 1996 | - | -$1.00 M(-50.0%) | -$6.50 M(-3.0%) |
| Mar 1996 | - | -$2.00 M(+25.0%) | -$6.70 M(-15.2%) |
| Dec 1995 | -$7.90 M(+14.5%) | -$1.60 M(-15.8%) | -$7.90 M(0.0%) |
| Sept 1995 | - | -$1.90 M(+58.3%) | -$7.90 M(-1.3%) |
| June 1995 | - | -$1.20 M(-62.5%) | -$8.00 M(-3.6%) |
| Mar 1995 | - | -$3.20 M(+100.0%) | -$8.30 M(+20.3%) |
| Dec 1994 | -$6.90 M | -$1.60 M(-20.0%) | -$6.90 M(+30.2%) |
| Sept 1994 | - | -$2.00 M(+33.3%) | -$5.30 M(+60.6%) |
| June 1994 | - | -$1.50 M(-16.7%) | -$3.30 M(+83.3%) |
| Mar 1994 | - | -$1.80 M | -$1.80 M |
FAQ
- What is BioCryst Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly FCF year-on-year change?
- What is BioCryst Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM FCF year-on-year change?
What is BioCryst Pharmaceuticals annual free cash flow?
The current annual FCF of BCRX is -$97.31 M
What is the all time high annual FCF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual free cash flow is -$4.60 M
What is BioCryst Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of BCRX is $8.19 M
What is the all time high quarterly FCF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly free cash flow is $25.75 M
What is BioCryst Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, BCRX quarterly free cash flow has changed by +$17.66 M (+186.42%)
What is BioCryst Pharmaceuticals TTM free cash flow?
The current TTM FCF of BCRX is -$56.73 M
What is the all time high TTM FCF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM free cash flow is $7.94 M
What is BioCryst Pharmaceuticals TTM FCF year-on-year change?
Over the past year, BCRX TTM free cash flow has changed by +$40.58 M (+41.70%)